在喀麦隆HIV阳性和HIV阴性女性中采用careHPV DNA检测与数字阴道镜增强的视觉检查同步联合筛查宫颈癌:初步筛查及一年随访结果
该研究在喀麦隆对913名既往未筛查的≥30岁女性同步进行careHPV DNA检测与数字阴道镜增强的视觉检查(VIA/VILI-DC),并按WHO建议对VIA/VILI-DC阳性者当日治疗。基线HR-HPV和HIV感染率分别为24%和42%。联合筛查可识别假阳性,但careHPV结果回报时间过长,无法支持当日治疗。
要点
- 初筛中44名(5%)VIA/VILI-DC阳性,其中22名HR-HPV阳性,50%筛查阳性者为假阳性。
- VIA/VILI-DC阳性者中,HIV阳性女性HR-HPV阳性率65%,HIV阴性女性为20%。
- 初筛HR-HPV阳性者一年后49%复查转阴,其中44%未治疗自发清除。
核心结论
- careHPV与VIA/VILI-DC联合筛查可行且有价值,能识别假阳性,但careHPV筛查至结果回报时间过长,无法支持当日治疗。
研究设计与样本
- 对913名既往未筛查的≥30岁喀麦隆女性同步进行careHPV DNA检测与数字阴道镜增强的醋酸和卢戈碘视觉检查(VIA/VILI-DC),并对所有VIA/VILI-DC阳性者按WHO推荐治疗。
- 初筛任一检测阳性者共245名,邀请一年后复查联合检测。
主要发现
- 初筛中44名(5%)VIA/VILI-DC阳性,其中22名HR-HPV阳性,50%筛查阳性者为假阳性并会被分诊接受不必要的当日治疗。
- VIA/VILI-DC阳性者中,HIV阳性女性HR-HPV阳性率65%,HIV阴性女性为20%,HIV阳性者HR-HPV阳性可能性为HIV阴性者的三倍。
- 245名初筛阳性者中136名(56%)完成一年随访;初筛HR-HPV阳性且复查的122名女性中60名(49%)复查转阴,其中6名初筛后接受治疗,44%初筛HR-HPV阳性女性一年后未治疗自发清除。
- 随访时HIV阳性女性持续HR-HPV阳性率61%,HIV阴性女性为22%(p<0.001)。
关键数值与推荐
- WHO宫颈癌筛查指南推荐在资源有限地区采用序贯筛查后当日治疗的「筛查-治疗」方案。
- 初筛所有VIA/VILI-DC阳性女性均接受治疗;随访时所有VIA/VILI-DC或HR-HPV阳性女性均接受治疗。
临床怎么用
- 作者认为careHPV与VIA/VILI-DC联合筛查可行且有价值,可识别假阳性,但careHPV结果回报时间过长,无法用于当日治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The World Health Organization (WHO)'s cervical cancer screening guidelines for limited-resource settings recommend sequential screening followed by same-day treatment under a "screen-and-treat" approach. We aimed to (1) assess feasibility and clinical outcomes of screening HIV-positive and HIV-negative Cameroonian women by pairing visual inspection with acetic acid and Lugol's iodine enhanced by digital cervicography (VIA/VILI-DC) with careHPV, a high-risk human papillomavirus (HR-HPV) nucleic acid test designed for low-resource settings; and (2) determine persistence of HR-HPV infection after one-year follow-up to inform optimal screening, treatment, and follow-up algorithms. METHODS: We co-tested 913 previously unscreened women aged ≥30years and applied WHO-recommended treatment for all VIA/VILI-DC-positive women. Baseline prevalence of HR-HPV and HIV were 24% and 42%, respectively. RESULTS: On initial screen, 44 (5%) women were VIA/VILI-DC-positive, of whom 22 had HR-HPV infection, indicating 50% of women screened false-positive and would have been triaged for unnecessary same-day treatment. VIA/VILI-DC-positive women with HIV infection were three times more likely to be HR-HPV-positive than HIV-negative women (65% vs. 20%). All women positive for either VIA/VILI-DC or HR-HPV (n=245) were invited for repeat co-testing after one year, of which 136 (56%) returned for follow-up. Of 122 women who were HR-HPV-positive on initial screen, 60 (49%) re-tested negative, of whom 6 had received treatment after initial screen, indicating that 44% of initially HR-HPV-positive women spontaneously cleared infection after one year without treatment. Women with HIV were more likely to remain HR-HPV-positive on follow-up than HIV-negative women (61% vs. 22%, p<0.001). Treatment was offered to all VIA/VILI-DC positive women on initial screen, and to all women screening VIA/VILI-DC or HR-HPV positive on follow-up. CONCLUSIONS: We found careHPV co-testing with VIA/VILI-DC to be feasible and valuable in identifying false-positives, but careHPV screening-to-result time was too long to inform same-day treatment.
引用
- Cholli P, Bradford L, Manga S, et al. Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up. Gynecol Oncol. 2017. PMID: 29153541. doi:10.1016/j.ygyno.2017.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。